Premium
Successful and safe long‐term treatment of cerebral aspergillosis with high‐dose voriconazole guided by therapeutic drug monitoring
Author(s) -
Cojutti Pier Giorgio,
Merelli Maria,
Allegri Lorenzo,
Damante Giuseppe,
Bassetti Matteo,
Pea Federico
Publication year - 2019
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13789
Subject(s) - voriconazole , medicine , aspergillosis , intensive care medicine , therapeutic drug monitoring , adverse effect , drug , pharmacology , antifungal , dermatology , immunology
We report the case of a patient who had cerebral aspergillosis after otorhinolaryngologic surgery and who was successfully and safely treated with high‐dose voriconazole (200 mg q6h) for more than 1 year thanks to a TDM‐guided approach coupled with pharmacological review and with genotyping of CYP2C19 polymorphisms. The findings support the idea that personalized medicine based on TDM coupled with the need of avoiding drug–drug interactions may be helpful for maximizing the net benefit (probability of efficacy vs . probability of adverse events) of voriconazole in the management of long‐term treatment of cerebral aspergillosis.